{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:16:55Z","timestamp":1791605815905,"version":"4.3.4"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005881","name":"Kultur\u00e1lis \u00e9s Innov\u00e1ci\u00f3s Miniszt\u00e9rium","doi-asserted-by":"publisher","award":["EK\\u00D6P-2024-31"],"award-info":[{"award-number":["EK\\u00D6P-2024-31"]}],"id":[{"id":"10.13039\/501100005881","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clim.2025.110542","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:56:39Z","timestamp":1749657399000},"page":"110542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["A national survey of four decades of hereditary angioedema prophylaxis: Efficacy and safety of old and new drugs"],"prefix":"10.1016","volume":"279","author":[{"given":"Hanga R\u00e9ka","family":"Horv\u00e1th","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Be\u00e1ta","family":"Visy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga Vikt\u00f3ria","family":"K\u0151halmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Balla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi","family":"Andr\u00e1si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibolya","family":"Czaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Zotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clim.2025.110542_bb0005","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaci.2024.03.024","article-title":"Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus","volume":"154","author":"Reshef","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2025.110542_bb0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2500\/aap.2019.40.4267","article-title":"Hereditary and acquired angioedema","volume":"40","author":"Patel","year":"2019","journal-title":"Allergy Asthma Proc."},{"issue":"7","key":"10.1016\/j.clim.2025.110542_bb0015","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema-the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.clim.2025.110542_bb0020","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00000441-188804000-00004","article-title":"Hereditary angio-neurotic oedema","volume":"95","author":"Osler","year":"1888","journal-title":"Am J Med Sci"},{"issue":"5","key":"10.1016\/j.clim.2025.110542_bb0025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14656566.2013.778826","article-title":"Current pharmacotherapy of bradykinin-mediated angioedema","volume":"14","author":"Farkas","year":"2013","journal-title":"Expert. Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.clim.2025.110542_bb0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12016-016-8553-8","article-title":"The story of angioedema: from Quincke to bradykinin","volume":"51","author":"Reshef","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"26","key":"10.1016\/j.clim.2025.110542_bb0035","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJM197612232952602","article-title":"Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities","volume":"295","author":"Gelfand","year":"1976","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.clim.2025.110542_bb0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0091-6749(81)90181-0","article-title":"Clinical and biochemical effects of stanozolol therapy for hereditary angioedema","volume":"68","author":"Sheffer","year":"1981","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2025.110542_bb0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.transci.2003.08.004","article-title":"Protease inhibitors in the treatment of hereditary angioedema","volume":"29","author":"Ritchie","year":"2003","journal-title":"Transfus. Apher. Sci."},{"issue":"1","key":"10.1016\/j.clim.2025.110542_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA medical advisory board 2020 guidelines for the Management of Hereditary Angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.clim.2025.110542_bb0055","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/eci.11.50","article-title":"Cinryze (C1-inhibitor) for the treatment of hereditary angioedema","volume":"7","author":"Gompels","year":"2011","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"12","key":"10.1016\/j.clim.2025.110542_bb0060","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","article-title":"Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor","volume":"376","author":"Longhurst","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.clim.2025.110542_bb0065","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s40265-018-0987-2","article-title":"Lanadelumab: First Global Approval","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.clim.2025.110542_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.10.015","article-title":"Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"148","author":"Zuraw","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"10.1016\/j.clim.2025.110542_bb0075","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jaip.2023.04.017","article-title":"Hereditary angioedema: a review of the current and evolving treatment landscape","volume":"11","author":"Betschel","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.clim.2025.110542_bb0080","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/all.16351","article-title":"Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: phase 3 open-label extension study","volume":"80","author":"Reshef","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.clim.2025.110542_bb0085","first-page":"1","article-title":"Worldwide prevalence of hereditary angioedema: a systematic review and meta-analysis","author":"Fisch","year":"2025","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.clim.2025.110542_bb0090","author":"Office HCS"},{"issue":"1 Suppl 2","key":"10.1016\/j.clim.2025.110542_bb0095","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S1081-1206(10)60584-4","article-title":"Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 international consensus algorithm for the diagnosis, therapy, and Management of Hereditary Angioedema","volume":"100","author":"Bowen","year":"2008","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"8","key":"10.1016\/j.clim.2025.110542_bb0100","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/all.12900","article-title":"The angioedema quality of life questionnaire (AE-QoL) - assessment of sensitivity to change and minimal clinically important difference","volume":"71","author":"Weller","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.clim.2025.110542_bb0105","article-title":"The validity and reliability of a Thai version of the angioedema control test: which recall period is preferable?","author":"Chularojanamontri","year":"2023","journal-title":"Asian Pac. J. Allergy Immunol."},{"issue":"6","key":"10.1016\/j.clim.2025.110542_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2020.02.038","article-title":"Validation of the angioedema control test (AECT)-a patient-reported outcome instrument for assessing angioedema control","volume":"8","author":"Weller","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.clim.2025.110542_bb0115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jaip.2023.09.009","article-title":"Lanadelumab in patients 2 to <12 years old with hereditary angioedema: results from the Phase 3 SPRING Study","volume":"12","author":"Maurer","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"3","key":"10.1016\/j.clim.2025.110542_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2023.12.019","article-title":"Once-daily Oral Berotralstat for long-term prophylaxis of hereditary angioedema: the open-label extension of the APeX-2 randomized trial","volume":"12","author":"Kiani-Alikhan","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.clim.2025.110542_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.03.057","article-title":"Randomized trial of the efficacy and safety of Berotralstat (BCX7353) as an Oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2)","volume":"9","author":"Wedner","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.clim.2025.110542_bb0130","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejogrb.2010.05.008","article-title":"The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey","volume":"152","author":"Czaller","year":"2010","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"4","key":"10.1016\/j.clim.2025.110542_bb0135","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.0954-6820.1972.tb04818.x","article-title":"Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study","volume":"192","author":"Blohm\u00e9","year":"1972","journal-title":"Acta Med. Scand."},{"issue":"3","key":"10.1016\/j.clim.2025.110542_bb0140","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1473-0502(03)00164-2","article-title":"How do we treat patients with hereditary angioedema","volume":"29","author":"Cicardi","year":"2003","journal-title":"Transfus. Apher. Sci."},{"issue":"9","key":"10.1016\/j.clim.2025.110542_bb0145","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM197208312870907","article-title":"Tranexamic acid therapy in hereditary angioneurotic edema","volume":"287","author":"Sheffer","year":"1972","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.clim.2025.110542_bb0150","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.iac.2017.04.003","article-title":"Prophylactic therapy for hereditary angioedema","volume":"37","author":"Longhurst","year":"2017","journal-title":"Immunol. Allergy Clin. N. Am."},{"issue":"2","key":"10.1016\/j.clim.2025.110542_bb0155","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1081-1206(10)60424-3","article-title":"Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients","volume":"100","author":"Bork","year":"2008","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"3","key":"10.1016\/j.clim.2025.110542_bb0160","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2362.2010.02402.x","article-title":"Long-term efficacy of danazol treatment in hereditary angioedema","volume":"41","author":"F\u00fcst","year":"2011","journal-title":"Eur. J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.clim.2025.110542_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2015.01.003","article-title":"Critical appraisal of androgen use in hereditary angioedema: a systematic review","volume":"114","author":"Riedl","year":"2015","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"21","key":"10.1016\/j.clim.2025.110542_bb0170","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1097\/CM9.0000000000002144","article-title":"Long-term prophylaxis of hereditary angioedema with danazol","volume":"135","author":"Xu","year":"2022","journal-title":"Chin. Med. J."},{"issue":"7","key":"10.1016\/j.clim.2025.110542_bb0175","first-page":"380","article-title":"Hepatocellular carcinoma after danazol treatment for hereditary angio-oedema","volume":"72","author":"Berkel","year":"2014","journal-title":"Neth. J. Med."},{"issue":"5","key":"10.1016\/j.clim.2025.110542_bb0180","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0168-8278(02)00035-1","article-title":"Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema","volume":"36","author":"Bork","year":"2002","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.clim.2025.110542_bb0185","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2340\/00015555-0057","article-title":"Hepatocellular focal nodular hyperplasia after danazol treatment for hereditary angio-oedema","volume":"86","author":"Helsing","year":"2006","journal-title":"Acta Derm. Venereol."},{"issue":"3","key":"10.1016\/j.clim.2025.110542_bb0190","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1159\/000370106","article-title":"Hepatocellular carcinoma in a noncirrhotic liver after long-term use of danazol for hereditary angioedema","volume":"7","author":"Rahal","year":"2014","journal-title":"Case Rep Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2025.110542_bb0195","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1007\/s12029-012-9402-5","article-title":"Danazol-induced hepatocellular carcinoma in a patient with hereditary angioedema","volume":"43","author":"Thoufeeq","year":"2012","journal-title":"J. Gastrointest. Cancer"},{"issue":"3","key":"10.1016\/j.clim.2025.110542_bb0200","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4103\/ANT.ANT_112_0109","article-title":"Intracranial hypertension associated with danazol withdrawal: a case report","volume":"16","author":"Wu","year":"2007","journal-title":"Acta Neurol. Taiwanica"},{"issue":"12","key":"10.1016\/j.clim.2025.110542_bb0205","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.clinthera.2008.12.021","article-title":"Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema","volume":"30","author":"Birjmohun","year":"2008","journal-title":"Clin. Ther."},{"issue":"9","key":"10.1016\/j.clim.2025.110542_bb0210","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0149-2918(01)80114-4","article-title":"A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids","volume":"23","author":"Shahidi","year":"2001","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.clim.2025.110542_bb0215","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.atherosclerosis.2007.09.025","article-title":"Long-term danazol prophylaxis does not lead to increased carotid intima-media thickness in hereditary angioedema patients","volume":"198","author":"Szegedi","year":"2008","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.clim.2025.110542_bb0220","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jaci.2004.12.1130","article-title":"Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema","volume":"115","author":"Sz\u00e9plaki","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2025.110542_bb0225","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.anai.2016.06.005","article-title":"Thyroid hormones and complement parameters in hereditary angioedema with C1-inhibitor deficiency","volume":"117","author":"Czaller","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.clim.2025.110542_bb0230","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13023-016-0386-2","article-title":"The effect of long-term danazol treatment on haematological parameters in hereditary angioedema","volume":"11","author":"K\u0151halmi","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clim.2025.110542_bb0235","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13023-014-0205-6","article-title":"Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema","volume":"9","author":"Zotter","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.clim.2025.110542_bb0240","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2500\/aap.2008.29.3107","article-title":"Appraisal of danazol prophylaxis for hereditary angioedema","volume":"29","author":"Craig","year":"2008","journal-title":"Allergy Asthma Proc."},{"issue":"4","key":"10.1016\/j.clim.2025.110542_bb0245","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00228-009-0771-z","article-title":"The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study","volume":"66","author":"Farkas","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"32","key":"10.1016\/j.clim.2025.110542_bb0250","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1556\/650.2017.30806","article-title":"Effect of danazol treatment on growth in pediatric patients with hereditary angioedema due to C1-inhibitor deficiency","volume":"158","author":"K\u0151halmi","year":"2017","journal-title":"Orv. Hetil."},{"issue":"3","key":"10.1016\/j.clim.2025.110542_bb0255","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/ccr3.3743","article-title":"Subcutaneous C1-inhibitor concentrate for prophylaxis during pregnancy and lactation in a patient with C1-INH-HAE","volume":"9","author":"Andarawewa","year":"2021","journal-title":"Clin. Case Reports"},{"issue":"6","key":"10.1016\/j.clim.2025.110542_bb0260","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1177\/0897190019857407","article-title":"Successful long-term prophylactic treatment with subcutaneous C1 esterase inhibitor in a patient with hereditary angioedema","volume":"33","author":"Hahn","year":"2020","journal-title":"J. Pharm. Pract."},{"issue":"3","key":"10.1016\/j.clim.2025.110542_bb0265","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227061","article-title":"New approach in prophylactic treatment of a challenged HAE patient","volume":"12","author":"Jordal","year":"2019","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.clim.2025.110542_bb0270","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/ced.12681","article-title":"Subcutaneous self-injections of C1 inhibitor: an effective and safe treatment in a patient with hereditary angio-oedema","volume":"41","author":"Weller","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.clim.2025.110542_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2022.818741","article-title":"Real-life experience with subcutaneous plasma-derived C1-inhibitor for long-term prophylaxis in patients with hereditary angioedema: a case series","volume":"3","author":"Zanichelli","year":"2022","journal-title":"Front Allergy."},{"issue":"7","key":"10.1016\/j.clim.2025.110542_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100664","article-title":"Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-Centre experience","volume":"15","author":"Abuzakouk","year":"2022","journal-title":"World Allergy Organ J."},{"issue":"2","key":"10.1016\/j.clim.2025.110542_bb0285","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5415\/apallergy.0000000000000102","article-title":"Experience of lanadelumab administration in hereditary angioedema: a case series of 4 patients in Portugal","volume":"13","author":"Bernardino","year":"2023","journal-title":"Asia Pac. Allergy"},{"key":"10.1016\/j.clim.2025.110542_bb0290","doi-asserted-by":"crossref","first-page":"1405317","DOI":"10.3389\/fimmu.2024.1405317","article-title":"The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center","volume":"15","author":"Buttgereit","year":"2024","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.clim.2025.110542_bb0295","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1016\/j.jaip.2021.04.072","article-title":"Lanadelumab efficacy, safety, and injection interval extension in HAE: a real-life study","volume":"9","author":"Buttgereit","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.clim.2025.110542_bb0300","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/all.15620","article-title":"Lanadelumab for the prevention of hereditary angioedema attacks: a real-world UK audit","volume":"78","author":"Dorr","year":"2023","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.clim.2025.110542_bb0305","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13223-022-00664-4","article-title":"Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France","volume":"18","author":"Fain","year":"2022","journal-title":"Allergy, Asthma Clin. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2025.110542_bb0310","doi-asserted-by":"crossref","first-page":"194","DOI":"10.29262\/ram.v70i3.1270","article-title":"Experiencia inicial de Lanadelumab en una paciente mexicana con angioedema hereditario tipo I","volume":"70","author":"Garc\u00eda-Rosas","year":"2023","journal-title":"Rev. Alerg. Mex."},{"issue":"10","key":"10.1016\/j.clim.2025.110542_bb0315","doi-asserted-by":"crossref","first-page":"978","DOI":"10.36849\/JDD.2020.5269","article-title":"Prospective analysis in patients with HAE under prophylaxis with Lanadelumab: a real-life experience","volume":"19","author":"Hahn","year":"2020","journal-title":"J. Drugs Dermatol."},{"issue":"9","key":"10.1016\/j.clim.2025.110542_bb0320","first-page":"390","article-title":"Successful use of Lanadelumab in an older patient with type II hereditary angioedema","volume":"39","author":"Hellu","year":"2022","journal-title":"Fed. Pract."},{"issue":"6","key":"10.1016\/j.clim.2025.110542_bb0325","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/1346-8138.17106","article-title":"Effect of lanadelumab on attack frequency and QoL in Japanese patients with hereditary angioedema: report of five cases","volume":"51","author":"Hioki","year":"2024","journal-title":"J. Dermatol."},{"issue":"1","key":"10.1016\/j.clim.2025.110542_bb0330","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13223-021-00579-6","article-title":"Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada","volume":"17","author":"Iaboni","year":"2021","journal-title":"Allergy, Asthma Clin. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2025.110542_bb0335","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/cts.12806","article-title":"Pharmacokinetics, pharmacodynamics, and exposure-response of Lanadelumab for hereditary angioedema","volume":"13","author":"Wang","year":"2020","journal-title":"Clin. Transl. Sci."},{"issue":"1\u20133","key":"10.1016\/j.clim.2025.110542_bb0340","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12016-024-09006-1","article-title":"Hereditary angioedema attacks in patients receiving long-term prophylaxis: a systematic review","volume":"67","author":"Longhurst","year":"2024","journal-title":"Clin. Rev. Allergy Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625001172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625001172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:37:48Z","timestamp":1762547868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661625001172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":68,"alternative-id":["S1521661625001172"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2025.110542","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A national survey of four decades of hereditary angioedema prophylaxis: Efficacy and safety of old and new drugs","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2025.110542","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110542"}}